Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Investomine’s Substack. In this ...

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

Eli Lilly (LLY) rated Sell/Avoid: overvaluation, slowing GLP-1 growth, Novo competition, bearish technicals and insider ...

Orforglipron's launch and Medicare/Medicaid eligibility will expand Eli Lilly's addressable market and offset price erosion.

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs top healthcare stocks. On March 10, analysts at Bernstein SocGen ...

LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a ...

Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...